Firering Strategic Minerals: From explorer to producer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,412.00
Bid: 12,410.00
Ask: 12,414.00
Change: 14.00 (0.11%)
Spread: 4.00 (0.032%)
Open: 12,432.00
High: 12,482.00
Low: 12,400.00
Prev. Close: 12,398.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-Recharged hopes of Brexit deal, trade truce power UK shares

Thu, 10th Oct 2019 09:40

* FTSE 100, FTSE 250 up 0.3%

* Mondi reverses course to close higher

* Miners biggest boost to main index

* FTSE 100 confirms "Death Cross" pattern
(Adds company news items, updates share moves, changes analyst
comments)

By Muvija M and Shashwat Awasthi

Oct 10 (Reuters) - London stocks finished a roller coaster
session on Thursday with gains as domestic companies rose after
Britain and Ireland said they saw a pathway to a Brexit deal,
and international names jumped on to a global rally over hopes
of a U.S.-China trade truce.

The FTSE 100 ended 0.3% higher, after flipping back
and forth during the day on mixed signals over the state of
affairs between Beijing and Washington, while the midcap index
that has a greater UK exposure also rose by the same level.

However, a more than 1% surge in sterling on renewed
prospects of a Brexit agreement kept a lid on gains for the
blue-chip bourse, which earns a sizeable portion of its earnings
in the U.S. dollar.

Spirits company Diageo, consumer goods giant
Unilever and AstraZeneca were among stocks
hammered the most, causing the FTSE 100 to lag other major
indexes.

Stocks vulnerable to a hit from Brexit, on the other hand,
overpowered those losses. Lloyds topped the main board
with a 4% leap, while Royal Bank of Scotland added 3%.

Mining heavyweights, which rely on world's top metals
consumer China for a chunk of their profits, were the biggest
sector-wise boost to the main bourse, climbing 2.5% - their most
since early August.

Gains were triggered as hopes of a resolution to a painfully
long trade war returned after U.S. President Donald Trump said
he will meet Chinese Vice Premier Liu He on Friday.

The comments were well received, given they came after
sentiment had turned sour following a report that Beijing has
urged Washington to stop unreasonable pressure on Chinese
companies.

On news-related moves, FTSE 100 component Mondi
reversed earlier losses to close 2% higher after a third-quarter
update, while homewares retailer Dunelm slumped 10% to
the bottom of the midcap index after it flagged a softer market.

Still, reflecting recent worries over trade and Brexit, the
FTSE 100 confirmed a "Death Cross" pattern as its 50-day moving
average (DMA) crossed below the 200 DMA, which is seen a warning
sign that more losses are likely in the near term.

The blue-chip bourse last formed the pattern roughly a year
ago when Brexit negotiations and Italy's budget deficit had hit
risk appetite.

"The ebb and flow of sentiment around U.S., China trade
continues to pull global stock markets from pillar to post," CMC
Markets' Michael Hewson wrote.

(Reporting by Muvija M and Shashwat Awasthi in Bengaluru;
Editing by Bernard Orr and Giles Elgood)

More News
20 Jun 2024 10:56

TOP NEWS: AstraZeneca's Truqap gets OK from EU for breast cancer form

(Alliance News) - AstraZeneca PLC on Thursday said that the EU approved its prescription medicine Truqap, in combination with hormonal therapy Faslodex, for the treatment of a form of breast cancer.

Read more
18 Jun 2024 09:33

TOP NEWS: AstraZeneca disappointed by breast cancer drug trial results

(Alliance News) - AstraZeneca PLC on Tuesday said findings from a breast cancer drug trial showed that Truqap did not meet its primary endpoints.

Read more
18 Jun 2024 07:51

LONDON BRIEFING: Ashtead profit declines; Whitbread sales rise

(Alliance News) - London's FTSE 100 is called to open higher on Tuesday, taking confidence from a decent showing for US equities overnight, with inflation data and central bank decisions the key plot points as the week progresses.

Read more
18 Jun 2024 07:17

AstraZeneca trial fails to treat 'challenging' breast cancer

(Sharecast News) - AstraZeneca announced on Tuesday that the phase three 'CAPItello-290' trial for 'Truqap', or capivasertib, in combination with paclitaxel did not achieve its primary endpoints.

Read more
17 Jun 2024 09:09

TOP NEWS: Astra's Imfinzi plus chemo approved for cancer form in US

(Alliance News) - AstraZeneca PLC on Monday said it secured a new US approval for cancer treatment Imfinzi, also known as durvalumab, hailing an "important new option" for patients.

Read more
17 Jun 2024 07:48

LONDON BRIEFING: Astra gets US drug approval; Ascential trades in line

(Alliance News) - London's FTSE 100 is called to open solidly higher on Monday, recovering some poise after a tricky week, with eyes turning to the Bank of England.

Read more
17 Jun 2024 07:23

IN BRIEF: AstraZeneca gets positive cancer test results for Calquence

AstraZeneca PLC - Cambridge, England-based pharmaceutical maker - Reports promising test results for one of its cancer therapies. The Echo phase III trial shows that Calquence, when used in combination with bendamustine and rituximab, demonstrates a clinically meaningful improvement in progression-free survival in patients with untreated mantle cell lymphoma. Compared to standard-of-care chemoimmunotherapy, the combination with Calquence, whose generic name is acalabrutinib, shows a 27% reduced risk of disease progression or death. Mantle cell lymphoma is rare and typically aggressive form of non-Hodgkin lymphoma, Astra explains.

Read more
17 Jun 2024 07:15

AstraZeneca's Imfinzi gets US approval for endometrial cancer patients

(Sharecast News) - AstraZeneca said its Imfinzi cancer treatment had been approved in the US as treatment for adult patients with primary advanced or recurrent endometrial cancer.

Read more
12 Jun 2024 20:56

AstraZeneca's Farxiga approved to treat paediatric type-2 diabetes

(Alliance News) - AstraZeneca PLC on Wednesday said its Farxiga treatment has been approved in the US to treat some diabetes sufferers.

Read more
10 Jun 2024 09:10

LONDON BROKER RATINGS: JPMorgan cuts Aviva but lifts M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and on Friday:

Read more
10 Jun 2024 08:30

TOP NEWS: Astra's Tagrisso gets US priority review for lung cancer

(Alliance News) - AstraZeneca PLC on Monday celebrated a breakthrough therapy designation for its cancer drug Tagrisso, aimed at treating a form of non-small cell lung cancer.

Read more
10 Jun 2024 07:37

LONDON BRIEFING: FTSE called down amid political uncertainty in EU

(Alliance News) - Stocks in London are called to open lower on Monday, setting off the week on the backfoot, with eyes on the US Federal Reserve's latest interest rate decision.

Read more
10 Jun 2024 06:25

London pre-open: Stocks set for lower start after EU elections

(Sharecast News) - Stocks in London look primed for a lower start as investors digest the gains made by far right parties in Austria, Germany, but above all France, at the European Union elections that were held at the weekend.

Read more
5 Jun 2024 09:52

LONDON BROKER RATINGS: Berenberg raises Taylor Wimpey to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
5 Jun 2024 09:27

AstraZeneca completes USD2.4 billion Fusion Pharmaceuticals purchase

(Alliance News) - AstraZeneca PLC on Wednesday said it successfully completed the acquisition of Boston, Massachusetts-based Fusion Pharmaceuticals Inc.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.